By performing a comprehensive plasma complement protein analysis, we showed significantly reduced levels of both C2 and C5 proteins in plasma of AChR-MG patients compared to controls, indicative of ongoing complement activation and consumption of these components (Figure 1). This evidence concerns the gene C2 and myasthenia gravis.